Drug discovery and development company ImmuPharma plc (LSE:IMM) said on Monday that its US partner, Avion Pharmaceuticals, is seeking final regulatory guidance from the US Food and Drug Administration (FDA) as it prepares for the start of the international Phase 3 trial of Lupuzor, a first-in class autophagy immunomodulator, in lupus patients.
Lupus (Systemic Lupus Erythematosus or SLE) is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs.
Avion has submitted positive results from the Lupuzor/P140 pharmacokinetic study to the FDA. This study met all the key endpoints and (in line with all human dosing to date) demonstrated that the treatment was safe and well tolerated across all doses and in all subjects.
As part of the licence and development agreement for Lupuzor entered into between Avion and ImmuPharma, the new international Phase 3 trial is being funded by Avion, which has the exclusive rights to commercialise Lupuzor in the US. The rest of the world rights remain with ImmuPharma.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax